Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis

Trial Profile

A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Pelican Expression Technology; Pfenex
  • Most Recent Events

    • 07 Oct 2019 According to a Pfenex media release, the company is conducting a comparative human factors study between PF708 and Forteo as requested by FDA. Pfenex anticipates submitting the final study report to the FDA as early as the second half of October 2019 and believes that this completes the information package required by the FDA to evaluate the therapeutic equivalence of PF708.
    • 07 Oct 2019 According to a Pfenex media release, the company announced that the U.S. Food and Drug Administration (FDA) has approved the new drug application for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug.
    • 08 Aug 2019 According to a Pfenex media release, the FDA has completed its mid-cycle review of NDA for PF708 in May and did not identify any issues that require an advisory committee meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top